EuroPCR 2018 | OxAMI-PICSO: Coronary Sinus Occlusion, Improving Microvascular Function and Reducing Infarct Size

The index of microcirculatory resistance might guide therapy and controlled intermittent coronary sinus occlusions, improve microvascular function, and reduce infarct size.

OxAMI-PICSO: oclusión del seno coronario: mejorar la función microvascular y reducir el tamaño del infartoThis study included patients with prior ST-segment elevation myocardial infarction treated with primary angioplasty. Researchers measured the index of microcirculatory resistance before stenting and intermittent coronary sinus occlusion was used if the result was higher than 40. Control of this group was provided through a historical control cohort of patients with infarction and an index of microcirculatory resistance higher than 40. Infarct size was measured through magnetic resonance imaging (MRI) at 48 hours and at 6 months.

 

The study included a total of 105 patients (25 who underwent coronary sinus occlusion, 50 control patients whose index before primary angioplasty was >40, and 30 patients whose index was ≤40).


Read also: Swedish Registry on the SYNERGY DES: tested in primary PCI for the first time.


When compared with control patients, subjects who underwent intermittent coronary sinus occlusion exhibited smaller infarct size in the MRI at 48 hours and at 6 months.

 

Conclusion

Patients whose index of microcirculatory resistance is >40 before primary angioplasty might benefit from coronary sinus occlusion for the reduction of infarct size.

 

Original title: Index of Microcirculatory Resistance-Guided Therapy with Pressure-Controlled Intermittent Coronary Sinus Occlusion Improves Coronary Microvascular Function and Reduces Infarct Size in Patients with ST-Elevation Myocardial Infarction: The Oxford Acute Myocardial Infarction – Pressure-controlled Intermittent Coronary Sinus Occlusion Study (OxAMI-PICSO Study).

Presenter: Giovanni Luigi De Maria.

 

OxAMI-PICSO-presentación

OxAMI-PICSO-artículo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....